Akebia Therapeutics Reports First Quarter 2022 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Akebia Therapeutics (AKBA) Misses Q1 EPS by 6c
May 9, 2022 4:22 PM EDTAkebia Therapeutics (NASDAQ: AKBA) reported Q1 EPS of ($0.35), $0.06 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $61.7 million versus the consensus estimate of $44.22 million.
GUIDANCE:
Akebia Therapeutics sees FY2022 revenue of $165-170 million.
For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.
... More